Handelsbanken Fonder Ab Fate Therapeutics Inc Transaction History

Handelsbanken Fonder Ab

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 11, 2022	SELL	$29.67 - $60.28 $56,373 - $114,532	-1,900 Reduced 12.5%	13,300 $516,000
Q2 2021 Aug 03, 2021	BUY	$67.25 - $92.52 $121,050 - $166,536	1,800 Added 13.43%	15,200 $1.32 Million
Q3 2020 Nov 13, 2020	BUY	$30.41 - $40.5 $88,189 - $117,450	2,900 Added 27.62%	13,400 $536,000
Q2 2020 Aug 13, 2020	BUY	$20.21 - $35.23 $212,205 - $369,914	10,500 New	10,500 $360,000

167

101M

41.3K

15.9K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $88.3M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Handelsbanken Fonder Ab, based on Form 13F filings with the SEC.

Stay updated on Handelsbanken Fonder Ab with notifications on news.